- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06397378
Engaging College Students in Developing and Testing a Video-based Intervention for HPV Vaccination Promotion (HPV videos)
Development and Pilot Testing a Video-based Intervention to Promote HPV Vaccination Among College Students
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Human papillomavirus (HPV) infection is the most common sexually transmitted infection in the United States (U.S.) and a significant public health issue, as almost all sexually active individuals contract it at some point in their lives. Approximately 79 million Americans are infected with HPV, most in their late teens or early 20s. HPV has been found to be associated with cancers for females (e.g., cervical cancer) and males (e.g., penile cancer). The high morbidity, mortality, and economic burden attributed to cancer-causing HPV call for researchers to address this public health concern through vigorous prevention efforts, including HPV vaccination.
HPV-associated cancers could be prevented through vaccination. HPV vaccination is recommended for individuals aged 9-26 years. Economic models have shown that HPV vaccination of adolescents and young adults is cost effective; however, HPV vaccination rates are falling dramatically short of the 80% Healthy People 2030 target recommendation. Young adults such as college students are at higher risk for HPV infection but a significant portion of them is not yet vaccinated against HPV.
Empirical evidence suggests that a lack of awareness and knowledge about HPV and the vaccine, the inconvenience of getting the vaccine, and concern about side effects are main barriers for college students. Current interventions developed to increase HPV vaccination rates are primarily focusing on adolescents as recipients. In the limited interventions developed to address low HPV vaccination rates among college students, most of them only included female college students. In one online RCT study that young adults aged 18-26 were randomized into intervention group (YouTube videos) reported significantly higher vaccination intention compared to comparison group (educational pamphlet); however, the vaccination status was not assessed. College students have advocated for educational videos featuring healthcare providers and peers and sharing videos on YouTube and Instagram.
To our knowledge, this study is the first one of a few video-based interventions co-designed with the main stakeholder-college students to address the low HPV vaccination rates in this at-risk population. This novel intervention is brief, portable, tailored to college students and feasible to fit the intervention into college student's busy schedules.
The investigators will develop a video-based intervention and conduct a pilot randomized trial comparing this intervention to an HPV Fact Sheet developed by CDC. The investigators will target college students aged 18-26 because of their higher risk of contracting HPV infection and low vaccination rates. Aim 1. Develop a developmentally and culturally congruent video-based intervention for college students aged 18-26. The investigators will recruit and form a student advisory board (SAB) consisting of 8-10 college students aged 18-26 to assist with developing four brief HPV education videos (each 2-3 mins long; two will be revised from Co-I's prior research). The advisory board will provide input on the study recruitment plan, assessments, and be involved in data interpretation and dissemination processes. Aim 2. Conduct a pilot randomized controlled trial (RCT) to examine the feasibility (participation rate, retention, intervention fidelity), acceptability (satisfaction) and preliminary efficacy of the intervention to promote HPV vaccination among 80 college students aged 18-26.
Once consented, participants will receive assessments at baseline (T0) using the web-based data collection tool, Qualtrics, before being assigned to one of the two study arms. Participants will be invited to fill out Time 1 (T1) assessment immediately after the intervention (video vs. Fact Sheet) and Time 2 (T2) assessment 2 months after completion of the intervention. The interventions (video and CDC Fact Sheet) and T0-T2 assessments will be administered online. A resource kit including available resources to obtain vaccines will be provided to all participants after T2 assessment. The investigators will also provide the video-based intervention to the students in the comparison arm after T2 assessment should they be interested. Videos will be sent out after participants complete T0. One video will be sent out every 3 days and the intervention (4 videos in total) will be completed in 2-week via emails. Participants in the intervention group can watch the videos at their leisure.
Feasibility will be assessed by response rate (percentage of eligible individuals agreeing to participate), retention (proportion retained through follow-up and complete T0-T2 assessments), intervention fidelity (% of participants watch all stories). Acceptability will be assessed via two Likert-type satisfaction questions. Based on our prior research, the investigators will use the following benchmarks to determine study feasibility as ≥ 80% response rate, ≥ 80% retention rate, ≥ 80% intervention fidelity, and acceptability by a mean satisfaction score ≥ 4.0. Preliminary efficacy will be determined by the % of participants completing the 1st HPV vaccine does within 2 months of completing the intervention.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: ChengChing Hiya Liu, Ph. D.
- Phone Number: 626-566-4835
- Email: chengliu@msu.edu
Study Contact Backup
- Name: Angela Chia-Chen Chen, Ph.D.
- Phone Number: 5173534747
- Email: chenang6@msu.edu
Study Locations
-
-
Michigan
-
East Lansing, Michigan, United States, 48824
- Recruiting
- Michigan State University
-
Contact:
- Cheng-Ching Hiya Liu, Ph.D.
- Phone Number: 626-566-4835
- Email: chengliu@msu.edu
-
Contact:
- Cheng-Ching Liu, Ph.D.
- Phone Number: 626-566-4835
- Email: chengliu@msu.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria: college students aged 18-26 never receive HPV vaccines able to understand English.
Exclusion Criteria: not able to understand English younger than 18 or older than 26 years old have received HPV vaccines.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Group using CDC factsheet
We did not develop this intervention.
Instead, we will use information from the CDC website on HPV and the HPV vaccine and convert it into a narrated voiceover video to ensure the information is delivered in the same format as our video-based intervention.
|
We did not develop this intervention. Instead, we will use information from the CDC website on HPV and the HPV vaccine and convert it into a video with a narrated voiceover format. Because our student advisory board will develop four short videos, participants who are randomly assigned to the CDC fact sheet group will watch the converted CDC video four times to ensure that all groups are exposed to the same number of videos. Here is the CDC link: https://www.cdc.gov/hpv/vaccines/?CDC_AAref_Val=https://www.cdc.gov/hpv/parents/vaccinesafety.html |
|
Experimental: Group using videos
Ninety-three college students will be randomly assigned to three groups (31 participants in each video group Vs. 30 participants in the CDC group) to watch the created videos.
The videos will be presented in randomized order and distributed to participants to minimize bias.
|
Eight college students created and developed four videos on human papillomavirus (HPV) and the HPV vaccine, designed to increase their knowledge and attitude, shape subjective norms, enhance perceived behavioral control, and strengthen intentions to receive the HPV vaccine. Two months after the video intervention, we will follow up with participants to collect their self-reported vaccine uptake status. Outcomes will be compared with those of another group whose participants will watch a video presenting CDC information on HPV and the HPV vaccine, adapted into a narrated voiceover format. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participants' HPV vaccination intention
Time Frame: through study completion, an average of 1 year
|
The investigators will assess participants' intention to receive HPV vaccines before and after watching HPV vaccine-related videos, t
|
through study completion, an average of 1 year
|
|
Participants' HPV vaccine uptake
Time Frame: through study completion, an average of 1 year
|
Participants will be asked if they received any HPV vaccines after watching the videos.
|
through study completion, an average of 1 year
|
|
Participants' attitude toward receiving the HPV vaccines
Time Frame: through study completion, an average of 1 year
|
Participants' attitude toward receiving HPV vaccines will be assessed before and after watching videos.
|
through study completion, an average of 1 year
|
|
Participants' subjective norms
Time Frame: through study completion, an average of 1 year
|
Participants' subjective norms regarding receiving HPV vaccines will be assessed before and after watching videos.
|
through study completion, an average of 1 year
|
|
Participants' perceived behavioral controls
Time Frame: through study completion, an average of 1 year
|
Participants' perceived behavioral control regarding receiving HPV vaccines will be assessed before and after watching videos.
|
through study completion, an average of 1 year
|
|
Participants' satisfaction
Time Frame: through study completion, an average of 1 year
|
participants' satisfaction about the interventions.
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Pathologic Processes
- Disease Attributes
- Infections
- Virus Diseases
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- DNA Virus Infections
- Tumor Virus Infections
- Pathological Conditions, Signs and Symptoms
- Papillomavirus Infections
Other Study ID Numbers
- MSUSTUDY10264
- PD66847 (Other Identifier: Michigan State University Trifecta Initiative Fubd)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on N/A - Healthy Subjects
-
Dr. Wang Man-PingThe Hong Kong Jockey Club Charities TrustNot yet recruiting
-
Bristol-Myers SquibbPfizerCompleted
-
Bristol-Myers SquibbPfizerCompletedN/A - Healthy SubjectsUnited States
-
New York Institute of TechnologyCompletedN/A Healthy IndividualsUnited States
-
Biotie Therapies Inc.PRA Health Sciences; Tandem Labs; Xceleron IncCompletedN/A, as Healthy VolunteersNetherlands
-
Washington University School of MedicineEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruitingA. Longitudinal Cohort n=400 | B. Lower Risk (n=45) and Higher Risk (n=105) Randomized 2:1 to PERCCS InterventionUnited States
-
Merz Pharmaceuticals GmbHCompletedN/A, as no Specific Medical Condition Will be TreatedGermany
-
Clavis PharmaCompletedNot Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy SubjectsUnited Kingdom
-
AstraZenecaCompletedElderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.Sweden
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
Clinical Trials on CDC HPV Fact Sheet
-
University of TorontoThe Hospital for Sick ChildrenCompletedMothers of Newborn InfantsCanada
-
M.D. Anderson Cancer CenterCompletedAdvanced CancersUnited States
-
Georgetown UniversityVirginia Commonwealth University; Basser Center for BRCA; Nueva Vida, Inc.; Capital... and other collaboratorsCompletedHereditary Breast and Ovarian Cancer SyndromeUnited States
-
The University of Texas Health Science Center at...Genentech, Inc.Active, not recruitingEducational ProblemsUnited States
-
Neuroscience Research AustraliaCompletedLow Back PainAustralia
-
Queen's University, BelfastBelfast Health and Social Care Trust; Public Health Agency (Northern Ireland); Dairy Council for Northern IrelandCompletedPregnancy Related | Iodine DeficiencyUnited Kingdom
-
Georgetown UniversityNational Cancer Institute (NCI); Virginia Commonwealth UniversityRecruitingHereditary Breast and Ovarian CancerUnited States
-
University of HawaiiCompleted
-
University of New MexicoKlein Buendel, Inc.Withdrawn
-
Servicio Canario de SaludCompletedGeneralized Anxiety Disorder | GADSpain